Skip to main content

Research Repository

Advanced Search

ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats

Garden, O A; Kidd, L; Mexas, A M; Chang, Y M; Jeffrey, U; Blois, S L; Fogle, J E; MacNeill, A L; Lubas, G; Birkenheuer, A; Buoncompagni, S; Dandrieux, J R S; Di Loria, A; Fellman, C L; Glanemann, B; Goggs, R; Granick, J L; LeVine, D N; Sharp, C R; Smith-Carr, S; Swann, J W; Szladovits, B


O A Garden

L Kidd

A M Mexas

Y M Chang

U Jeffrey

S L Blois

J E Fogle

A L MacNeill

G Lubas

A Birkenheuer

S Buoncompagni

J R S Dandrieux

A Di Loria

C L Fellman

B Glanemann

R Goggs

J L Granick

D N LeVine

C R Sharp

S Smith-Carr

J W Swann

B Szladovits


Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were
written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability
before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.


Garden, O. A., Kidd, L., Mexas, A. M., Chang, Y. M., Jeffrey, U., Blois, S. L., …Szladovits, B. (in press). ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. Journal of Veterinary Medical Education,

Journal Article Type Article
Acceptance Date Jan 18, 2019
Deposit Date Mar 19, 2019
Publicly Available Date Mar 20, 2019
Print ISSN 0748-321X
Publisher University of Toronto Press
Peer Reviewed Peer Reviewed
Public URL


Downloadable Citations